DK1725544T3 - 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme - Google Patents

3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme

Info

Publication number
DK1725544T3
DK1725544T3 DK05724523T DK05724523T DK1725544T3 DK 1725544 T3 DK1725544 T3 DK 1725544T3 DK 05724523 T DK05724523 T DK 05724523T DK 05724523 T DK05724523 T DK 05724523T DK 1725544 T3 DK1725544 T3 DK 1725544T3
Authority
DK
Denmark
Prior art keywords
benzamides
triazol
heterocyclyl
inhibitors
aryl
Prior art date
Application number
DK05724523T
Other languages
Danish (da)
English (en)
Inventor
Derek Cogan
Ming-Hong Hao
Victor Marc Kamhi
Craig A Miller
M R Netherton
Alan D Swinamer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1725544T3 publication Critical patent/DK1725544T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
DK05724523T 2004-03-09 2005-03-04 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme DK1725544T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55144504P 2004-03-09 2004-03-09
PCT/US2005/006997 WO2005090333A1 (fr) 2004-03-09 2005-03-04 3-'4-heterocyclyl -1,2,3,-triazol-1-yl-n-aryl-benzamides en tant qu'inhibiteurs de la production de cytokines pour le traitement de maladies inflammatoires

Publications (1)

Publication Number Publication Date
DK1725544T3 true DK1725544T3 (da) 2009-07-27

Family

ID=34962594

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05724523T DK1725544T3 (da) 2004-03-09 2005-03-04 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme

Country Status (30)

Country Link
US (2) US7214802B2 (fr)
EP (2) EP1725544B1 (fr)
JP (1) JP4850824B2 (fr)
KR (1) KR20060129077A (fr)
CN (1) CN1930144A (fr)
AR (1) AR048315A1 (fr)
AT (1) ATE432273T1 (fr)
AU (1) AU2005223738B2 (fr)
BR (1) BRPI0508561A (fr)
CA (1) CA2557856C (fr)
CY (1) CY1109333T1 (fr)
DE (1) DE602005014621D1 (fr)
DK (1) DK1725544T3 (fr)
EA (1) EA011634B1 (fr)
EC (1) ECSP066833A (fr)
ES (1) ES2327940T3 (fr)
HR (1) HRP20090334T1 (fr)
IL (1) IL177937A0 (fr)
MY (1) MY143000A (fr)
NO (1) NO20064120L (fr)
NZ (1) NZ550148A (fr)
PE (1) PE20051146A1 (fr)
PL (1) PL1725544T3 (fr)
PT (1) PT1725544E (fr)
RS (1) RS50796B (fr)
SI (1) SI1725544T1 (fr)
TW (1) TW200602313A (fr)
UA (1) UA85702C2 (fr)
WO (1) WO2005090333A1 (fr)
ZA (1) ZA200606177B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121390A1 (fr) * 2006-04-18 2007-10-25 Boehringer Ingelheim International Gmbh Procede de preparation de composes inhibiteurs des cytokines contenant des cycles 4- et 5-imidazolyle et leurs intermediaires
NZ574621A (en) * 2006-07-07 2012-03-30 Boehringer Ingelheim Int Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumour agents
AU2007292155B2 (en) 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
EP2176249A2 (fr) * 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH Nouveaux composés chimiques
US8278340B2 (en) * 2007-11-27 2012-10-02 North Carolina State University Inhibition of biofilms in plants with imidazole derivatives
WO2009123753A1 (fr) * 2008-04-04 2009-10-08 North Carolina State University Inhibition de biofilms bactériens par des dérivés d'imidazole-phényle
WO2009131654A2 (fr) * 2008-04-21 2009-10-29 North Carolina State University Inhibition et dispersion de films biologiques bactériens avec dérivés d'imidazole-triazole
AU2009289329A1 (en) 2008-09-02 2010-03-11 Neurosearch A/S Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
JP2012504137A (ja) 2008-09-29 2012-02-16 アボット・ラボラトリーズ インドール誘導体およびインドリン誘導体ならびにそれらの使用方法
UY32146A (es) * 2008-09-29 2010-04-30 Boehringer Ingelheim Int Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
WO2010077603A1 (fr) 2008-12-08 2010-07-08 North Carolina State University Inhibition et dispersion de biofilms dans des plantes avec dérivés d'imidazole-triazole
WO2010094695A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Dérivés pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
WO2010144686A1 (fr) 2009-06-10 2010-12-16 North Carolina State University Inhibition et dispersion de bio-films bactériens avec dérivés de benzimidazole
WO2011008312A2 (fr) 2009-07-14 2011-01-20 Abbott Laboratories Dérivés indole et indoline et leurs procédés d’utilisation
WO2011084434A2 (fr) 2009-12-17 2011-07-14 Abbott Laboratories Dérivés d'indole et d'indoline à cycles condensés et pontage aza
WO2011084433A2 (fr) 2009-12-17 2011-07-14 Abbott Laboratories Indoles et indolines à cycles condensés et pontage aza
MX2012007031A (es) 2009-12-17 2012-07-04 Abbott Lab Indoles e indolinas fusionadas al anillo amina de cabeza de puente utiles para tratar transtornos neurodegenerativos y neuropsiquiatricos.
EP2521451A4 (fr) 2010-01-07 2013-08-21 Selexagen Therapeutics Inc Inhibiteurs de la voie hedgehog
WO2011085261A1 (fr) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Inhibiteurs de hedgehog
WO2011117381A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Inhibiteurs de kinase b-raf
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2012067822A1 (fr) 2010-11-16 2012-05-24 Abbott Laboratories Modulateurs des canaux potassiques à base de pyrazolo[1,5-a]pyrimidine
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
PT2668183T (pt) * 2011-01-28 2018-02-05 4Sc Discovery Gmbh Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune
EA027351B1 (ru) * 2011-01-28 2017-07-31 4-Эс-Си Дискавери Гмбх Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112016010164A2 (pt) * 2013-11-05 2017-08-08 Bayer Cropscience Ag novos compostos para o combate aos ártropodes
TW201730189A (zh) 2015-12-23 2017-09-01 吉斯藥品公司 激酶抑制劑
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
JP7391055B2 (ja) * 2018-07-04 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１４２アゴニストとしてのトリアゾールベンズアミド誘導体
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
JOP20220087A1 (ar) 2019-10-11 2023-01-30 Incyte Corp أمينات ثنائية الحلقة كمثبطات لـ cdk2
WO2022188792A1 (fr) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique ayant une activité inhibitrice de protéine kinase, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
JP3418624B2 (ja) * 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
JP4385414B2 (ja) * 1997-10-13 2009-12-16 アステラス製薬株式会社 アミド若しくはアミン誘導体
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
JP2002510679A (ja) * 1998-04-08 2002-04-09 アボット・ラボラトリーズ ピラゾールサイトカイン産生阻害剤
AU4229999A (en) * 1998-06-05 1999-12-20 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
USRE45616E1 (en) 1998-10-13 2015-07-21 Covidien Lp Multi-channel non-invasive tissue oximeter
EP1123287B1 (fr) 1998-10-23 2003-07-30 Dow AgroSciences LLC 1-(pyridile substitue)-1,2,4-triazoles insecticides
US6451820B1 (en) * 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
CA2458533C (fr) 2001-10-09 2011-01-04 Tularik Inc. Derives d'imidazole comme agents anti-inflammatoires
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EP1618092B1 (fr) * 2003-05-01 2010-09-22 Bristol-Myers Squibb Company Composes de pyrazole-amide substitues par aryle utilises comme inhibiteurs de la kinase

Also Published As

Publication number Publication date
KR20060129077A (ko) 2006-12-14
RS50796B (sr) 2010-08-31
NO20064120L (no) 2006-09-26
ECSP066833A (es) 2006-11-24
PL1725544T3 (pl) 2009-10-30
AU2005223738B2 (en) 2011-08-11
ATE432273T1 (de) 2009-06-15
MY143000A (en) 2011-02-14
UA85702C2 (ru) 2009-02-25
EA011634B1 (ru) 2009-04-28
EA200601571A1 (ru) 2007-02-27
WO2005090333A8 (fr) 2006-08-24
CN1930144A (zh) 2007-03-14
ES2327940T3 (es) 2009-11-05
JP4850824B2 (ja) 2012-01-11
EP1725544A1 (fr) 2006-11-29
NZ550148A (en) 2010-07-30
SI1725544T1 (sl) 2009-10-31
PT1725544E (pt) 2009-07-02
AU2005223738A1 (en) 2005-09-29
HRP20090334T1 (en) 2009-07-31
WO2005090333A1 (fr) 2005-09-29
CA2557856A1 (fr) 2005-09-29
ZA200606177B (en) 2008-12-31
PE20051146A1 (es) 2006-02-02
IL177937A0 (en) 2006-12-31
CA2557856C (fr) 2010-06-29
DE602005014621D1 (de) 2009-07-09
EP1887003A1 (fr) 2008-02-13
BRPI0508561A (pt) 2007-08-14
US20070142371A1 (en) 2007-06-21
EP1725544B1 (fr) 2009-05-27
US20060079519A1 (en) 2006-04-13
JP2007528395A (ja) 2007-10-11
CY1109333T1 (el) 2014-07-02
AR048315A1 (es) 2006-04-19
US7214802B2 (en) 2007-05-08
TW200602313A (en) 2006-01-16
US7514458B2 (en) 2009-04-07

Similar Documents

Publication Publication Date Title
DK1725544T3 (da) 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme
LTC1907382I2 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
CY2013014I2 (el) Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
IL182212A0 (en) Indazolone derivatives as 11b-hsd1 inhibitors
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
NL1029015A1 (nl) Therapeutische verbindingen.
WO2010038086A8 (fr) Nouveaux composés
IL180187A (en) Composition for treating inflammatory disorders
DE602005000849D1 (de) Kältekammer
DK1776090T3 (da) Stabiliseret prostaglandinsammensætning
DK1704145T3 (da) Selektive kinaseinhibitorer
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DE602005017957D1 (de) Regelungsverfahren für Wärmepumpen
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
DK1713805T3 (da) Kinaseinhibitorer
DK1871380T3 (da) Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DK1784349T3 (da) Lagerreol
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
ITTO20050018A1 (it) Struttura per la disposizione di cuscinetti.
ES1058317Y (es) Kit para la fabricacion de balaustres.
FR2877958B1 (fr) Nouvelle structure de plancher en bois
ITRM20040285A1 (it) Piattelli per la fabbricazione di crepes.